CLINICAL_TRIALS
ClinicalTrials.gov record update
The Effectiveness and Safety of Lenvatinib Combined Anti-programmed Death Immunotherapy for the Advanced Hepatocellular Carcinoma
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04627012
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:39:55.343165+00:00
- Published At
- 2024-03-06T00:00:00+00:00
- Record Updated At
- 2024-03-06
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Hepatocellular Carcinoma", "Anti-PD1 Antibody", "Liver Diseases"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-03-06"- protocolSection.identificationModule.nctId
"NCT04627012"- protocolSection.identificationModule.officialTitle
"The Effectiveness and Safety of Lenvatinib Combined Anti-programmed Death Immunotherapy for the Advanced Hepatocellular Carcinoma"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
[]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.